Tabula Rasa HealthCare Stock Quote 43T - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

Bid

Ask

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Previous Close

Open

Last Trade

Last Trade Time

Average Volume (3m)

Financial Volume

VWAP

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet needs...

Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need...

Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Long-term KRESLADITM follow-up data demonstrate survival of 100% in the absence of allogeneic hematopoietic stem cell transplantation (HSCT) from 18 to 45 months with a well-tolerated safety...

Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress

Advanced RP-L102 for Fanconi Anemia towards regulatory reviews; EMA accepted MAA for review and BLA submission anticipated in the first half of 2024 Continued preparations to launch LV portfolio...

Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Positive, previously disclosed results from the global Phase 1/2 trial demonstrated genetic and phenotypic correction combined with hematologic stabilization extending out to 42 months after...

Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team

Aaron Ondrey joins as Chief Financial Officer bringing seasoned leadership experience in financial management, strategic planning, commercial finance, and capital allocation Additional key...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
9S70Critical Resources Limited	0.006 € (50.00%)	166.67k
PW2Powell Industries, Inc.	169.00 € (37.06%)	725
BDDConico Ltd	0.0008 € (33.33%)	125k
PUBPancontinental Energy NL	0.0115 € (27.78%)	6k
7S2Scotch Creek Ventures Inc	0.0234 € (27.17%)	20.4k
CBOImunon Inc	1.34 € (-56.21%)	56.43k
1FGFibroGen Inc	0.4858 € (-49.27%)	73.21k
HHHAHomes & Holiday AG	0.07 € (-48.15%)	240
LK1Lake Resources	0.014 € (-40.17%)	2.25k
EJ7Energy Resources of Australia	0.009 € (-35.72%)	252k
D7GNel ASA	0.5052 € (-2.09%)	2.21M
DMLSayona Mining Limited	0.0197 € (7.65%)	1.14M
LHADeutsche Lufthansa AG	5.782 € (-2.10%)	1.07M
NVDNVIDIA Corp	106.82 € (11.56%)	876.42k
OY4Mogotes Metals Inc	0.107 € (25.44%)	827.91k